# Intravacc B.V.

Canonical: https://abierto.us/vendors/intravacc-b-v-ry3newmnza63

- UEI: RY3NEWMNZA63
- CAGE: H2MN6
- Location: Bilthoven, NLD
- Awards in window: 2 (8 transactions), $63,594 obligated, January 10, 2025 to August 20, 2026

## Awarding agencies

- National Institutes of Health: 2 awards, $63,594

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $63,594

## Competition

- Full and Open Competition: 2 awards

## Largest awards

- 75N93022C00058 (definitive contract): $1,174,464, National Institutes of Health Niaid. Development of an Intranasal Vaccine Against Gonorrhea Based on Outer Membrane Vesicles Combined with Sustained-Release Microspheres Containing Recombinant Human Interleukin-12.. https://www.usaspending.gov/award/CONT_AWD_75N93022C00058_7529_-NONE-_-NONE-/
- 75N93020C00037 (definitive contract): -$1,110,870, National Institutes of Health Niaid. To Develop an Intramuscular Inactivated Whole Virus Vaccine from Early Product Selection Through a Phase I Clinical Trial to Induce Protection Against Ev D68 Induced Afm.. https://www.usaspending.gov/award/CONT_AWD_75N93020C00037_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/intravacc-b-v-ry3newmnza63.